About Boehringer Ingelheim
Boehringer Ingelheim is a Healthcare company based in Ingelheim Am Rhein (Germany) founded in 1885. Generic drugs and clinical research services are provided globally. Boehringer Ingelheim has completed 16 acquisitions, including AMAL Therapeutics, AbeXXa Biologics and Actimis. Its chief executive, as recorded, is Jean-Michel Boers. Its website boehringer-ingelheim.com draws about 1.6 million monthly visits. Its Indian entity Boehringer Ingelheim India Private Limited reported revenue of ₹665 Cr. Its focus areas include Biopharma Outsourcing, Diversified, Small Molecules & Peptides and Diversified Pharmaceuticals.
Company details
Boehringer Ingelheim was founded in 1885 as a pharmaceutical entity focused on generic drugs and clinical research services. Operations are centered in the healthcare sector, with emphasis on drug development and research support. Leadership includes Co-CEO Jean-Michel Boers, CEO Hubertus Von Baumbach, and Managing Director Fei Shen. The company maintains a presence through its domain boehringer-ingelheim.com, though specific location details are not specified.
- Headquarters Ingelheim Am Rhein, Germany
- SectorsHealthcare
- Website category Health
- Email••••••••
- Phone•••• ••••
- Website boehringer-ingelheim.com
- Social LinkedIn X Facebook
- Legal Name Boehringer Ingelheim India Private Limited
- Date of Incorporation 11 Dec, 2003
- Indian entity revenue₹665 Cr
FY 2026 · -37% YoY
- Indian entity net profit₹20.36 Cr
FY 2026 · 3% margin
- Indian entity EBITDA₹46.63 Cr
FY 2026 · 7% margin
- Latest Funding Round$268.81K (USD), Grant
Sep 2022
- Investors
- Investments & AcquisitionsAMAL Therapeutics
& 15 more
Associated legal entities of Boehringer Ingelheim
Boehringer Ingelheim operates through Boehringer Ingelheim India Private Limited (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2026) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Boehringer Ingelheim India Private Limited CIN U24230MH2003PTC143499 | Active | 11 Dec 2003 | Mumbai, Maharashtra | ₹665 Cr | 744 | 5 | View details |
Apps and channels of Boehringer Ingelheim
Boehringer Ingelheim publishes 1 mobile app with over 10K+ downloads.
Funding Insights of Boehringer Ingelheim
- Total Rounds 11
- Last Round Grant — $268,807
- First Round $541,298
(Jan 2016)
- Investors Count 1
Latest 10 of 11 funding rounds of Boehringer Ingelheim with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep 2022 | $268,807 | Grant | – | – | |
| Jul 2022 | $439,540 | Grant | – | – | |
| Mar 2021 | $318,168 | Grant | – | – | |
| Dec 2020 | $11.47M | Grant | – | – | |
| Jan 2020 | $297,782 | Grant | – | – | |
| Sep 2019 | $306,681 | Grant | – | – | |
| Jan 2019 | $306,681 | Grant | – | – | |
| Jan 2019 | Grant | – | – | ||
| Dec 2017 | $6.64M | Grant | – | – | |
| Apr 2017 | $3.86M | Grant | – | – |
1 investors in total: 1 institutional.
Investors in Boehringer Ingelheim
Boehringer Ingelheim has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include European Union.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability | 1958 | europa.eu | Brussels, Belgium |
Investor details for Boehringer Ingelheim
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Board of directors of Boehringer Ingelheim India Private Limited (Boehringer Ingelheim)
Boehringer Ingelheim India Private Limited is the primary company behind Boehringer Ingelheim. The board of Boehringer Ingelheim India Private Limited currently have 5 directors; the longest-serving is Sandipkumar Rameshchandra Agrawal, appointed in 2017. 13 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Sandipkumar Rameshchandra Agrawal DIN 07958499 | Director | 11 Oct 2017 | 9 yrs 1 mo | Boehringer Ingelheim India Private Limited |
| Sanjay Srivastava DIN 09795065 | Director | 21 Nov 2022 | 3 yrs 11 mo | Boehringer Ingelheim India Private Limited |
| Shriya Mandar Oak DIN 10627911 | Director | 23 May 2024 | 2 yrs 5 mo | Boehringer Ingelheim India Private Limited |
| Meenal Gauri DIN 11421321 | Managing Director | 12 Jan 2026 | 10 mo | Boehringer Ingelheim India Private Limited |
| Vinod Gopal DIN 12023469 | Director | 03 Nov 2026 | Boehringer Ingelheim India Private Limited |
People of Boehringer Ingelheim
278 people are tracked at Boehringer Ingelheim (148 in leadership, 130 in team).
| Name | Role | Group |
|---|---|---|
Jean-Michel Boers | Co-CEO & President | Leadership |
Hubertus Von Baumbach | CEO & Chairman | Leadership |
Fei Shen | Managing Director | Leadership |
Felipe Aquino | Head Of Tax | Leadership |
Belén Vilaplana | Head Of IT Quality & Compliance Europe | Leadership |
Sandeep Mora | Director | Leadership |
Golo Heckmann | Head Of API & Chemical Process Development Animal Health | Leadership |
Brad Smith | Executive Director, Controlling, U.s. Animal Health Commercial Business | Leadership |
Shashank Deshpande | Managing Director, Animal Health | Leadership |
Pia Schall | General Manager And HP Head Poland | Leadership |
Chiara Strano | Regional Head Governance And Transformation | Leadership |
Naveen Ketha | Sr Associate Director Digital Analytics | Leadership |
Max Booker | Director, Digital Channel Excellence (us Animal Health - Commercial Excellence) | Leadership |
Rod Christmas | Chief Veterinary Officer | Leadership |
Daya Nair | Senior Associate Director, Digital Marketing - Pets | Leadership |
Michael Schmelmer | Managing Director, Finance & Group Functions | Leadership |
Feryal Tanriverdio | Head PSPV Digital Innovation | Leadership |
Stefan Vielhauer | Head of Analytical Innovation Center | Leadership |
Leidy Rincón C. | Head Of Structured Transactions (m&a) | Leadership |
Nessim Rahali | Head Of FACT (finance, Accounting, Controlling & Tax), Imeta | Leadership |
258 more people are available in the full profile.
Complete people profiles for Boehringer Ingelheim
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Financials of Boehringer Ingelheim
Figures of Boehringer Ingelheim India Private Limited, the primary company behind Boehringer Ingelheim, for FY 2026. Revenue was ₹665 Cr (-37% year on year). Net profit was ₹20.36 Cr (3% margin). EBITDA was ₹46.63 Cr (7% margin). Revenue has grown at a compounded annual rate of -16% over three years and -11% over five years.
- ₹665 CrRevenue · FY 2026 · -37% YoY
- ₹20.36 CrNet profit · 3% margin
- ₹46.63 CrEBITDA · 7% margin
- ₹6.47 CrPaid-up capital
- 744Employees (provident fund records)
- -16%Revenue CAGR, 3 years
- -11%Revenue CAGR, 5 years
Balance sheet, profit and loss, cash flow and ratios of Boehringer Ingelheim India Private Limited are on its company page.
Detailed financial statements for Boehringer Ingelheim
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Boehringer Ingelheim
Boehringer Ingelheim has strategically engaged in corporate development activities, having acquired 16 companies. Notable acquisitions include AMAL Therapeutics, AbeXXa Biologics and Actimis.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Vaccines and drugs against pet diseases are developed. | saiba-animalhealth.com | Zurich, Switzerland | 2013 | Sep 2024 | •••• | |
Technology for immunotherapy drug discovery is developed via high-throughput screening. | neriotx.com | La Jolla, United States | 2019 | Jul 2024 | •••• | |
Novel cancer medicines are developed using a bacteria-based platform. | t3pharma.com | Basel, Switzerland | 2015 | Nov 2023 | $509.27M | |
Cytokines for cancer treatment are developed with tumor-site activation. | trutinobio.com | San Diego, United States | 2017 | Jun 2022 | •••• | |
Next-generation antibody-based therapeutics are developed by AbeXXa Biologics. | abexxa.com | Lewes, United States | 2015 | Sep 2021 | •••• | |
Antibody-drug conjugates for cancer treatment are developed. | nbe-therapeutics.com | Basel, Switzerland | 2012 | Dec 2020 | $1.43B | |
Bioanalytical services for vaccines and viral therapeutics are provided. | labormerk.com | Ochsenhausen, Germany | 1971 | Dec 2020 | •••• | |
Blood-derived mesenchymal stem cells are developed for veterinary clinical applications. | gst.be | Evergem, Belgium | 2012 | Jul 2020 | •••• | |
Antibody therapeutics are developed for oncology and fibrosis indications. | northernbiologics.com | Toronto, Canada | 2014 | May 2020 | •••• | |
AMAL Therapeutics is focused on developing therapeutic cancer vaccines. | amaltherapeutics.com | Geneva, Switzerland | 2012 | Jul 2019 | $366.22M |
Complete acquisition details for Boehringer Ingelheim
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Boehringer Ingelheim
13 dated milestones of Boehringer Ingelheim across 139 years, from founding to its latest funding, stage changes and deals.
- Founded Boehringer Ingelheim is founded.
- Funding First funding round of $541K.
- Acquisition Acquires AMAL Therapeutics.
- Acquisition Acquires Northern Biologics.
- Acquisition Acquires Global Stem cell Technology.
- Acquisition Acquires Labor Dr. Merk & Kollegen.
- Acquisition Acquires NBE Therapeutics.
- Acquisition Acquires AbeXXa Biologics.
- Acquisition Acquires Trutino Biosciences.
- Funding Latest funding round, Grant, of $269K.
- Acquisition Acquires T3 Pharma.
- Acquisition Acquires Nerio.
- Acquisition Acquires Saiba Animal Health.
Web traffic of Boehringer Ingelheim
The website of Boehringer Ingelheim (boehringer-ingelheim.com) receives about 1.6M visits a month and ranks #39,825 among all websites worldwide, #995 in Health.
- Monthly visits1.6M
▲ 9.6% vs previous month
- Unique visitors822.8K
per month
- Global rank#39,825
among all websites
- Category rank#995
Health · Health
- Bounce rate49%
- Pages per visit2.5
- Average visit1 min 21 sec
- DevicesDesktop 41% · Mobile 59%
Websites whose visitors overlap most with Boehringer Ingelheim. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| bms.com | 100% | 809.8K | #67,210 | View details | |
| abbott.com | 99% | 917.2K | #65,577 | View details | |
| lilly.com | 98% | 4.9M | #13,252 | View details | |
| gsk.com | 93% | 1.3M | #56,834 | View details | |
| pfizer.com | 85% | 1.9M | #24,984 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 40 similar websites and full traffic analytics for Boehringer Ingelheim
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 40 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Boehringer Ingelheim
Complete news archive for Boehringer Ingelheim
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Boehringer Ingelheim
Boehringer Ingelheim was founded in 1885 and raised its 1st funding round 131 years after it was founded.
Boehringer Ingelheim is headquartered in Ingelheim Am Rhein, Germany. It is registered at Ingelheim Am Rhein, Rheinland-pfalz, Germany.
Jean-Michel Boers is the CEO of Boehringer Ingelheim, as recorded in our data.
The primary company behind Boehringer Ingelheim, Boehringer Ingelheim India Private Limited, reported revenue of ₹665 Cr for FY 2026, down 37% year on year.
Boehringer Ingelheim was founded in 1885 as a pharmaceutical entity focused on generic drugs and clinical research services. Operations are centered in the healthcare sector, with emphasis on drug development and research support. Leadership includes Co-CEO Jean-Michel Boers, CEO Hubertus Von Baumbach, and Managing Director Fei Shen. The company maintains a presence through its domain boehringer-ingelheim.com, though specific location details are not specified.
Boehringer Ingelheim has made 16 acquisitions, including AMAL Therapeutics, AbeXXa Biologics, and Actimis.
Boehringer Ingelheim has 1 investor. Key investors include European Union.
Boehringer Ingelheim operates through Boehringer Ingelheim India Private Limited.
The legal entities of Boehringer Ingelheim currently have 5 directors, including Sandipkumar Rameshchandra Agrawal, Sanjay Srivastava, Shriya Mandar Oak and others.
Yes. Boehringer Ingelheim publishes First Aid For Pets, with over 10,000 downloads.
The website of Boehringer Ingelheim receives about 1.6 million visits a month and ranks #39,825 among all websites worldwide.